Scarica l'app Stockscreener
1.34
0.74%
-0.01
Dopo l'orario di chiusura:
1.31
-0.03
-2.24%
Precedente Chiudi:
$1.35
Aprire:
$1.35
Volume 24 ore:
239.27K
Relative Volume:
0.20
Capitalizzazione di mercato:
$71.30M
Reddito:
-
Utile/perdita netta:
$-51.47M
Rapporto P/E:
-1.34
EPS:
-1
Flusso di cassa netto:
$-47.50M
1 W Prestazione:
-4.29%
1M Prestazione:
-14.10%
6M Prestazione:
+47.90%
1 anno Prestazione:
-15.72%
Intervallo 1D:
$1.30
$1.36
Intervallo di 1 settimana:
$1.30
$1.44
Portata 52W:
$0.81
$1.84
Pmv Pharmaceuticals Inc Stock (PMVP) Company Profile
Nome
Pmv Pharmaceuticals Inc
Settore
Industria
Telefono
(609) 642-6670
Indirizzo
400 ALEXANDER PARK DRIVE, PRINCETON
Confronta PMVP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PMVP
Pmv Pharmaceuticals Inc
|
1.34 | 71.84M | 0 | -51.47M | -47.50M | -1.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.32 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
429.80 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
917.93 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
209.02 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Pmv Pharmaceuticals Inc Stock (PMVP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-08 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-05-13 | Iniziato | Craig Hallum | Buy |
| 2024-04-12 | Iniziato | Jefferies | Buy |
| 2023-12-27 | Iniziato | Ladenburg Thalmann | Buy |
| 2022-03-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2021-09-22 | Aggiornamento | Goldman | Neutral → Buy |
| 2021-08-19 | Iniziato | Oppenheimer | Perform |
| 2021-08-02 | Iniziato | Guggenheim | Buy |
| 2021-07-29 | Iniziato | H.C. Wainwright | Buy |
| 2020-10-20 | Iniziato | BofA Securities | Buy |
| 2020-10-20 | Iniziato | Cowen | Outperform |
| 2020-10-20 | Iniziato | Evercore ISI | Outperform |
| 2020-10-20 | Iniziato | Goldman | Neutral |
Mostra tutto
Pmv Pharmaceuticals Inc Borsa (PMVP) Ultime notizie
PMV Pharmaceuticals (NASDAQ:PMVP) versus Aurinia Pharmaceuticals (NASDAQ:AUPH) Financial Comparison - Defense World
Why PMV Pharmaceuticals Inc. stock is a must watch in 2025Trade Risk Summary & Safe Entry Zone Identification - newser.com
Why PMV Pharmaceuticals Inc. stock appeals to analysts2025 Retail Activity & Precise Swing Trade Entry Alerts - newser.com
Contrasting PMV Pharmaceuticals (NASDAQ:PMVP) & Kiora Pharmaceuticals (NASDAQ:KPRX) - Defense World
Is PMV Pharmaceuticals Inc. stock poised for growth2025 Market Sentiment & Free AI Powered Buy and Sell Recommendations - newser.com
How rising interest rates impact PMV Pharmaceuticals Inc. stockPortfolio Profit Report & Reliable Price Breakout Alerts - newser.com
Will PMV Pharmaceuticals Inc. stock outperform Dow Jones index2025 Price Targets & Real-Time Price Movement Reports - newser.com
Will PMV Pharmaceuticals Inc. stock benefit from commodity pricesCEO Change & Growth Oriented Trading Recommendations - newser.com
Is PMV Pharmaceuticals Inc. stock safe for conservative investorsJuly 2025 Momentum & Free High Return Stock Watch Alerts - newser.com
Is PMV Pharmaceuticals Inc. building a consolidation base2025 Volatility Report & Stock Portfolio Risk Control - newser.com
Top Penny Stocks To Watch In November 2025 - simplywall.st
Can PMV Pharmaceuticals Inc. stock deliver surprise earnings beat2025 Fundamental Recap & Safe Investment Capital Preservation Plans - newser.com
HC Wainwright Issues Positive Outlook for PMVP Earnings - Defense World
Published on: 2025-11-16 01:59:30 - newser.com
Real time social sentiment graph for PMV Pharmaceuticals Inc.2025 Geopolitical Influence & Reliable Breakout Stock Forecasts - newser.com
Sio Capital Management, LLC Reduces Stake in PMV Pharmaceuticals Inc - GuruFocus
PMV Pharmaceuticals Places Big Bet On Cancer Drug Rezatapopt - Finimize
PMV Pharmaceuticals Reports Increased Quarterly Loss - TipRanks
Buy Rating Affirmed for PMV Pharmaceuticals Amid Stable Financials and Strategic Growth Potential - TipRanks
PMV Pharma (PMVP) Plans NDA Submission for Ovarian Cancer Treatm - GuruFocus
PMV Pharmaceuticals Reports Third Quarter 2025 Financial Results and Corporate Highlights - The Manila Times
PMV Pharma Q3 net loss widens to $21.1 mln - MarketScreener
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 - MarketScreener
[10-Q] PMV Pharmaceuticals, Inc. Quarterly Earnings Report | PMVP SEC FilingForm 10-Q - Stock Titan
[8-K] PMV Pharmaceuticals, Inc. Reports Material Event | PMVP SEC FilingForm 8-K - Stock Titan
PMV Pharma (NASDAQ: PMVP) posts 46% ORR in ovarian cancer; median 8.0-month response - Stock Titan
Pmv Pharmaceuticals Inc Azioni (PMVP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.53%
1.88%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):